Summary

for people ages 60-85 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Official Title

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease

Keywords

Alzheimer Disease (AD) Memory problems Cognitive impairment PERISCOPE-ALZ Dementia Tauopathy Neurofibrillary tangles Alzheimer Disease LY3303560 LY3303560 Dose 1 LY3303560 Dose 2

Eligibility

You can join if…

Open to people ages 60-85

  • Participants must have gradual and progressive change in memory function for >6 months.
  • Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.

You CAN'T join if...

  • Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.
  • Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.
  • Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.
  • Participants must not have serious risk for suicide.
  • Participants must not have history of drug or alcohol use disorder within the last 2 years.
  • Participants must not have multiple severe drug allergies
  • Participants must not have HIV, Hepatitis B or Hepatitis C
  • Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin(IVIG) therapy

Locations

  • Univ of California San Francisco not yet accepting patients
    San Francisco California 94158 United States
  • National Research Institute accepting new patients
    Panorama City California 91402 United States
  • Pharmacology Research Institute accepting new patients
    Encino California 91316 United States
  • Fullerton Neurology and Headache Center accepting new patients
    Fullerton California 92835 United States
  • Pharmacology Research Institute accepting new patients
    Los Alamitos California 90720 United States
  • Syrentis Clinical Research accepting new patients
    Santa Ana California 92705 United States
  • Anderson Clinical Research accepting new patients
    Redlands California 92374 United States
  • Irvine Clinical Research Center accepting new patients
    Irvine California 92614 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT03518073
Phase
Phase 2
Study Type
Interventional
Last Updated
September 11, 2018